ESSITY-B Stock Analysis: Essity (publ) | ST
Household & Personal Products | ST, Sweden | Market Cap: 178.250m SEK | 12M Return: 6.7% | SE0009922164 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 337M
EPS Trend: 53.5%
Qual. Beats: -1
Rev. Trend: -92.5%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 9.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Essity AB (publ) is a Swedish hygiene and health products company founded in 1849 and headquartered in Stockholm. It operates through three segments: Health & Medical (incontinence, wound care, compression therapy, and orthopedics), Consumer Goods (feminine care, baby care, tissues, and toilet paper), and Professional Hygiene (away-from-home washroom and cleaning solutions), with sales reaching customers across Europe, the Americas, and Asia.
Classified within the Consumer Staples sector under Personal Care Products, the company runs a brand-driven business model built on well-known names such as TENA, Libresse, Zewa, Tempo, and Tork. Its distribution spans retail and e-commerce for consumer items alongside B2B direct sales and distributor networks for medical and professional hygiene customers.
- TENA incontinence sales accelerate on aging global demographics
- Pulp and energy costs remain key margin swing factor
- Tork Professional Hygiene rebounds with out-of-home traffic recovery
- Private label competition pressures European Consumer Goods pricing
| Net Income: 12.1b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.24 > 1.0 |
| NWC/Revenue: 3.37% < 20% (prev 11.79%; Δ -8.42% < -1%) |
| CFO/TA 0.10 > 3% & CFO 17.9b > Net Income 12.1b |
| Net Debt (39.7b) to EBITDA (25.7b): 1.54 < 3 |
| Current Ratio: 1.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (680.1m) vs 12m ago -1.65% < -2% |
| Gross Margin: 33.31% > 18% (prev 32.66%; Δ 0.65% > 0.5%) |
| Asset Turnover: 78.85% > 50% (prev 85.56%; Δ -6.71% > 0%) |
| Interest Coverage Ratio: 16.24 > 6 (EBIT TTM 18.5b / Interest Expense TTM 1.14b) |
| A: 0.03 (Total Current Assets 57.1b - Total Current Liabilities 52.5b) / Total Assets 182b |
| B: 0.45 (Retained Earnings 81.3b / Total Assets 182b) |
| C: 0.11 (EBIT TTM 18.5b / Avg Total Assets 174b) |
| D: 1.05 (Book Value of Equity 92.8b / Total Liabilities 88.4b) |
| Altman-Z'' = 3.44 = A |
| DSRI: 1.10 (Receivables 28.4b/26.9b, Revenue 138b/143b) |
| GMI: 0.98 (GM 32.66% / 33.31%) |
| AQI: 1.04 (AQ_t 0.39 / AQ_t-1 0.38) |
| SGI: 0.96 (Revenue 138b / 143b) |
| TATA: -0.03 (NI 12.1b - CFO 17.9b) / TA 182b) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of September 14, 2026, the stock is trading at SEK 261.30 with a total of 901,921 shares traded. Over the past week, the price has changed by -4.00%, over one month by -6.01%, over three months by -0.50% and over the past year by +6.69%.
Current recommended Stop Loss: 256.00 (which is 2% or 1.3 ATR below the current price).
Essity (publ) has no consensus analysts rating.
P/E Trailing = 14.8731
P/E Forward = 13.7552
P/S = 1.2957
P/B = 1.9573
P/EG = 3.2746
Revenue TTM = 138b SEK
EBIT TTM = 18.5b SEK
EBITDA TTM = 25.7b SEK
Long Term Debt = 27.7b SEK (from longTermDebt, last fiscal year)
Short Term Debt = 17.1b SEK (from shortTermDebt, last quarter)
Debt = 46.6b SEK (from shortLongTermDebtTotal, last quarter) + Leases 3.96b
Net Debt = 39.7b SEK (calculated: Debt 46.6b - CCE 6.87b)
Enterprise Value = 218b SEK (178b + Debt 46.6b - CCE 6.87b)
Interest Coverage Ratio = 16.24 (Ebit TTM 18.5b / Interest Expense TTM 1.14b)
EV/FCF = 20.06x (Enterprise Value 218b / FCF TTM 10.9b)
FCF Yield = 4.99% (FCF TTM 10.9b / Enterprise Value 218b)
FCF Margin = 7.90% (FCF TTM 10.9b / Revenue TTM 138b)
Net Margin = 8.81% (Net Income TTM 12.1b / Revenue TTM 138b)
Gross Margin = 33.31% ((Revenue TTM 138b - Cost of Revenue TTM 91.7b) / Revenue TTM)
Gross Margin QoQ = 32.65% (prev 33.48%)
Tobins Q-Ratio = 1.20 (Enterprise Value 218b / Total Assets 182b)
Interest Expense / Debt = 2.45% (Interest Expense 1.14b / Debt 46.6b)
Taxrate = 26.22% (4.33b / 16.5b)
NOPAT = 13.7b (EBIT 18.5b * (1 - 26.22%))
Current Ratio = 1.09 (Total Current Assets 57.1b / Total Current Liabilities 52.5b)
Debt / Equity = 0.50 (Debt 46.6b / totalStockholderEquity, last quarter 92.8b)
Debt / EBITDA = 1.54 (Net Debt 39.7b / EBITDA 25.7b)
Debt / FCF = 3.65 (Net Debt 39.7b / FCF TTM 10.9b)
Total Stockholder Equity = 87.4b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.94% (Net Income 12.1b / Total Assets 182b)
RoE = 13.86% (Net Income TTM 12.1b / Total Stockholder Equity 87.4b)
RoCE = 16.08% (EBIT 18.5b / Capital Employed (Equity 87.4b + L.T.Debt 27.7b))
RoIC = 9.81% (NOPAT 13.7b / Invested Capital 139b)
WACC = 4.74% (E(178b)/V(225b) * Re(5.51%) + D(46.6b)/V(225b) * Rd(2.45%) * (1-Tc(0.26)))
Discount Rate = 5.51% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -99.46 | Cagr: -1.42%
[DCF] Terminal Value 77.97% ; FCFF base≈9.70b ; Y1≈11.1b ; Y5≈16.4b
[DCF] Fair Price = 332.5 (EV 246b - Net Debt 39.7b = Equity 207b / Shares 621.2m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 53.46 | EPS CAGR: 2.15% | SUE: -0.88 | # QB: -1
Revenue Correlation: -92.51 | Revenue CAGR: -7.70% | SUE: 0.64 | # QB: 0
EPS current Quarter (2026-09-30): EPS=4.55 | Chg30d=-4.11% | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=18.83 | Chg30d=-0.78% | Revisions=+0% | GrowthEPS=+2.0% | GrowthRev=+1.8%
EPS next Year (2027-12-31): EPS=20.49 | Chg30d=-0.90% | Revisions=-40% | GrowthEPS=+8.8% | GrowthRev=+3.8%
[Analyst] Revisions Ratio: -22% (up=2, down=4)